The Danish pharmaceutical giant Novo Nordisk increased its operating profit by 57 percent in the first six months of 2015 to 26.3 billion kroner.

The company’s sales increased by 25 percent to 52.3 billion kroner in the same period.

The global leader in insulin and diabetes care has come a long way since 1989 when two small Danish companies, Nordisk Insulin Laboratory and Novo Therapeutic Laboratory, merged.

Large market value
Novo Nordisk is Denmark’s largest company by market value, which is currently assessed by Citibank to be about 2,300 billion kroner.

The company employs some 40,000 employees worldwide, of which 16,669 (42 percent) are employed in Denmark.

While the headquarters are located in Denmark, the company has manufacturing facilities in seven other countries and subsidiaries or offices in 74 countries.